Search

Your search keyword '"Niyonzima N"' showing total 74 results

Search Constraints

Start Over You searched for: Author "Niyonzima N" Remove constraint Author: "Niyonzima N"
74 results on '"Niyonzima N"'

Search Results

2. In VitroNeutralization ofNaja najaVenom Enzymes by Folk Medicinal Plant Extracts

5. Scorpion Toxin Polyptides as Therapeutic Agents: An Overview

8. In Vitro Neutralization of Naja naja Venom Enzymes by Folk Medicinal Plant Extracts.

9. In VitroNeutralization of Naja najaVenom Enzymes by Folk Medicinal Plant Extracts

13. The regional cancer spectrum in Uganda: a population-based cancer survey by sub-regions (2017-2020).

14. FOXP3 serum concentration; a likely predictor of CIN and cervical cancer: Secondary analysis from a case control study at a clinic in South western Uganda.

15. Association between fetal hemoglobin, lactate dehydrogenase, and disease severity in patients with sickle cell disease at Bugando Medical Centre, Mwanza, Tanzania.

16. The diagnostic accuracy of serum and plasma microRNAs in detection of cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta -analysis.

17. Coverage and Socioeconomic Inequalities in Cervical Cancer Screening in Low- and Middle-Income Countries Between 2010 and 2019.

18. Prevalence of cervical intraepithelial lesions and associated factors among women attending a cervical cancer clinic in Western Uganda; results based on Pap smear cytology.

19. Association between serum P16ink4A concentration and CIN and cervical cancer among women attending a cervical cancer clinic in western Uganda: A case control study.

20. Dyslipidemia: prevalence and association with precancerous and cancerous lesions of the cervix; a pilot study.

21. Review of Herbal Medicinal Plants Used in the Management of Cancers in the East Africa Region from 2019 to 2023.

22. Lived Experiences of Patients on Hemodialysis Treatment at Kiruddu National Referral Hospital: A Phenomenological Study.

23. Medicinal plants used in the management of cancers by residents in the Elgon Sub-Region, Uganda.

24. Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.

25. The impact of the COVID-19 pandemic on cancer care including innovations implemented in Sub-Saharan Africa: A systematic review.

26. Scaling up availability, accessibility, quality and equity - highlights from the 4th Uganda conference on cancer and palliative care, held in Kampala, Uganda.

27. Mycobacterium tuberculosis infection and cytogenetic abnormalities among people with HIV.

28. Access to Radiation Therapy and Related Clinical Outcomes in Patients With Cervical and Breast Cancer Across Sub-Saharan Africa: A Systematic Review.

29. The diagnostic accuracy of serum microRNAs in detection of cervical cancer: a systematic review protocol.

30. Socioeconomic inequalities in prostate cancer screening in low- and middle-income countries: An analysis of the demographic and health surveys between 2010 and 2019.

31. Pediatric, adolescent, and young adult cancer in an HIV-infected rural sub-Saharan African population.

32. Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.

33. Unique circulating microRNA profiles in epidemic Kaposi's sarcoma.

34. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute.

35. Genetic diversity of local and introduced cassava germplasm in Burundi using DArTseq molecular analyses.

36. Mitochondrial C5aR1 activity in macrophages controls IL-1β production underlying sterile inflammation.

37. Cancer and palliative care in COVID-19 and other challenging situations-highlights from the Uganda Cancer Institute-Palliative Care Association of Uganda 3rd Uganda Conference on Cancer and Palliative Care, 23-24 September 2021, held in Kampala, Uganda and virtually.

38. Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care.

39. Strengthening Laboratory Diagnostic Capacity to Support Cancer Care in Uganda.

40. Increasing access to quality anticancer medicines in low- and middle-income countries: the experience of Uganda.

41. Complement's favourite organelle-Mitochondria?

42. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.

43. Capacity building for cancer prevention and early detection in the Ugandan primary healthcare facilities: Working toward reducing the unmet needs of cancer control services.

44. Breast Cancer Clinical Trials: The Landscape at the Uganda Cancer Institute and Lessons Learned.

45. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2015 and 2019 at the Uganda Cancer Institute.

46. Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis.

47. Mobile cancer prevention and early detection outreach in Uganda: Partnering with communities toward bridging the cancer health disparities through "asset-based community development model".

48. A health care professionals training needs assessment for oncology in Uganda.

49. The human microbiome and its link in prostate cancer risk and pathogenesis.

50. Breast cancer treatment: A phased approach to implementation.

Catalog

Books, media, physical & digital resources